Form 4: BioMarin Director Elaine J. Heron Reports Acquisition of 4,720 Shares of Common Stock

Director Elaine J. Heron reported acquiring 4,720 shares of BioMarin Pharmaceutical Inc. common stock on May 21, 2024, and now beneficially owns 96,841 shares.

Summary

• On May 23, 2024, a Form 4 filing was submitted to the SEC, reporting changes in beneficial ownership for Elaine J. Heron, a director at BioMarin Pharmaceutical Inc.
• The report indicates that on May 21, 2024, Ms. Heron acquired 4,720 shares of common stock.
• These shares were acquired at a price of $0, likely indicating a grant of restricted stock units.
• Following this transaction, Ms. Heron's total beneficial ownership of BioMarin common stock is 96,841 shares.
• The filing also includes a Power of Attorney, dated December 6, 2023, authorizing G. Eric Davis, Tae Sang Yoo, and Eric Fleekop to act on Ms. Heron's behalf for Section 16 filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating insider transactions, which can be seen as a positive sign of confidence but doesn't provide enough information to strongly influence sentiment.

Positives

• The acquisition of shares by a director could be interpreted positively by investors, signaling confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency to investors regarding the actions of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.

Key Dates